Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Site Tools

  • AAAS
  • Subscribe
  • Feedback

Site Search

Search Advanced

Science 19 July 1985:
Vol. 229. no. 4710, pp. 289 - 291
DOI: 10.1126/science.2861661
Prev | Table of Contents | Next

Articles

Science, Vol 229, Issue 4710, 289-291
Copyright © 1985 by American Association for the Advancement of Science

articles

Reduced numbers of somatostatin receptors in the cerebral cortex in Alzheimer's disease

MF Beal, MF Mazurek, VT Tran, G Chattha, ED Bird, and JB Martin

Somatostatin receptor concentrations were measured in patients with Alzheimer's disease and controls. In the frontal cortex (Brodmann areas 6, 9, and 10) and temporal cortex (Brodmann area 21), the concentrations of somatostatin in receptors in the patients were reduced to approximately 50 percent of control values. A 40 percent reduction was seen in the hippocampus, while no significant changes were found in the cingulate cortex, postcentral gyrus, temporal pole, and superior temporal gyrus. Scatchard analysis showed a reduction in receptor number rather than a change in affinity. Somatostatin-like immunoreactivity was significantly reduced in both the frontal and temporal cortex. Somatostatin-like immunoreactivity was linearly related to somatostatin-receptor binding in the cortices of Alzheimer's patients. These findings may reflect degeneration of postsynaptic neurons or cortical afferents in the patients' cerebral cortices. Alternatively, decreased somatostatin-like immunoreactivity in Alzheimer's disease might indicate increased release of somatostatin and down regulation of postsynaptic receptors.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Brain Somatostatin Receptors Are Up-Regulated In Somatostatin-Deficient Mice.
J. L. Ramirez, R. Mouchantaf, U. Kumar, V. Otero Corchon, M. Rubinstein, M. J. Low, and Y. C. Patel (2002)
Mol. Endocrinol. 16, 1951-1963
   Abstract »    Full Text »    PDF »
Enhancement of Memory in Alzheimer Disease With Insulin and Somatostatin, but Not Glucose.
S. Craft, S. Asthana, J. W. Newcomer, C. W. Wilkinson, I. T. Matos, L. D. Baker, M. Cherrier, C. Lofgreen, S. Latendresse, A. Petrova, et al. (1999)
Arch Gen Psychiatry 56, 1135-1140
   Abstract »    Full Text »    PDF »
Neuropeptide Abnormalities in Patients With Early Alzheimer Disease.
K. L. Davis, R. C. Mohs, D. B. Marin, D. P. Purohit, D. P. Perl, M. Lantz, G. Austin, and V. Haroutunian (1999)
Arch Gen Psychiatry 56, 981-987
   Abstract »    Full Text »    PDF »
Neuropeptides in Alzheimer's disease: Somatostatin, Neuropeptide Y, and Galanin.
N. R. Cutler (1990)
American Journal of Alzheimer's Disease and Other Dementias 5, 7-12
   PDF »
Cerebrospinal Fluid Somatostatin and Neuropeptide Y: Concentrations in Aging and in Dementia of the Alzheimer Type With and Without Extrapyramidal Signs.
J. R. Atack, M. F. Beal, C. May, J. A. Kaye, M. F. Mazurek, A. D. Kay, and S. I. Rapoport (1988)
Arch Neurol 45, 269-274
   Abstract »    PDF »
Perspectives on the Etiology of Alzheimer's Disease.
H. N. Mozar, D. G. Bal, and J. T. Howard (1987)
JAMA 257, 1503-1507
   Abstract »    PDF »
Alzheimer's disease: clinical, neuropathologic, neuropsychologic, and brain metabolic findings.
N. R. Cutler and P. K. Narang (1986)
American Journal of Alzheimer's Disease and Other Dementias 1, 16-23
   Abstract »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)